Author + information
- Received January 7, 2018
- Revision received February 15, 2018
- Accepted February 17, 2018
- Published online July 16, 2018.
- Michael Joner, MDa,k,∗ (, )
- Tobias Koppara, MDb,k,
- Robert A. Byrne, MB, BCh, PhDa,k,
- Maria Isabel Castellanos, PhDa,k,
- Jonas Lewerich, MSa,
- Julia Novotny, MDc,
- Giulio Guagliumi, MDd,
- Erion Xhepa, MDa,
- Tom Adriaenssens, MDe,
- Thea C. Godschalk, MScf,
- Nikesh Malik, MD, PhDg,
- Fernando Alfonso, MDh,
- Tomohisa Tada, MDa,
- Franz-Josef Neumann, MDi,
- Walter Desmet, MD, PhDe,
- Jurrien M. ten Berg, MD, PhDe,
- Anthony H. Gershlick, MDg,
- Laurent J. Feldman, MD, PhDj,
- Steffen Massberg, MDc,k,
- Adnan Kastrati, MDa,k,
- on behalf of the Prevention of PRESTIGE Investigators
- aDeutsches Herzzentrum München, Technische Universität München, Munich, Germany
- bKlinik und Poliklinik für Innere Medizin I, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
- cMedizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität, Munich, Germany
- dAzienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
- eDepartment of Cardiology, University Hospitals Leuven, and Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
- fDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands
- gDepartment of Cardiovascular Sciences, University of Leicester & Leicester NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom
- hHospital Universitario de La Princesa, Madrid, Spain
- iUniversitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany
- jDépartement de Cardiologie, AP-HP, DHU FIRE, U-1148 INSERM, Hôpital Bichat, Paris, France
- kGerman Centre for Cardiovascular Research, partner site Munich Heart Alliance, Munich, Germany
- ↵∗Address for correspondence:
Prof. Dr. Michael Joner, Deutsches Herzzentrum München, Klinik an der Technischen Universität München, Lazarettstrasse 36, 80636 Munich, Germany.
Objectives The purpose of this study was to assess neoatherosclerosis in a registry of prospectively enrolled patients presenting with stent thrombosis using optical coherence tomography.
Background In-stent neoatherosclerosis was recently identified as a novel disease manifestation of atherosclerosis after coronary stent implantation.
Methods Angiography and intravascular optical coherence tomography were used to investigate etiologic factors of neoatherosclerosis in patients presenting with stent thrombosis >1 year after implantation (very late stent thrombosis [VLST]). Clinical data were collected according to a standardized protocol. Optical coherence tomographic acquisitions were analyzed in a core laboratory. Cox regression analysis was performed to identify factors associated with the formation of neoatherosclerosis and plaque rupture as a function of time.
Results Optical coherence tomography was performed in 134 patients presenting with VLST. A total of 58 lesions in 58 patients with neoatherosclerosis were compared with 76 lesions in 76 patients without neoatherosclerosis. Baseline characteristics were similar between groups. In-stent plaque rupture was the most frequent cause (31%) in all patients presenting with VLST. In patients with neoatherosclerosis, in-stent plaque rupture was identified as the cause of VLST in 40 cases (69%), whereas uncovered stent struts (n = 22 [29%]) was the most frequent cause in patients without neoatherosclerosis. Macrophage infiltration was significantly more frequent in optical coherence tomographic frames with plaque rupture compared with those without (50.2% vs. 22.2%; p < 0.0001), whereas calcification was more often observed in frames without plaque rupture (17.2% vs. 4%; p < 0.0001). Implantation of a drug-eluting stent was significantly associated with the formation of neoatherosclerosis (p = 0.02), whereas previous myocardial infarction on index percutaneous coronary intervention was identified as a significant risk factor for plaque rupture in patients with neoatherosclerosis (p = 0.003). No significant difference was observed in thrombus composition between patients with or without neoatherosclerosis.
Conclusions Neoatherosclerosis was frequently observed in patients with VLST. Implantation of a drug-eluting stent was significantly associated with neoatherosclerosis formation. In-stent plaque rupture was the prevailing pathological mechanism and often occurred in patients with neoatherosclerosis and previous myocardial infarction at index percutaneous coronary intervention. Increased macrophage infiltration heralded plaque vulnerability in our study and might serve as an important indicator.
The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement HEALTH-F2-2010-260309 (PRESTIGE). Funding for open-access publication is provided by the European Commission. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received January 7, 2018.
- Revision received February 15, 2018.
- Accepted February 17, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.